Pfizer (PFE) : Barrow Hanley Mewhinney Strauss reduced its stake in Pfizer by 8.83% during the most recent quarter end. The investment management company now holds a total of 48,981,192 shares of Pfizer which is valued at $1,721,688,899 after selling 4,743,574 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Pfizer makes up approximately 2.53% of Barrow Hanley Mewhinney Strauss’s portfolio.
Other Hedge Funds, Including , Flippin Bruce Porter Inc boosted its stake in PFE in the latest quarter, The investment management firm added 9,054 additional shares and now holds a total of 271,188 shares of Pfizer which is valued at $9,532,258. Pfizer makes up approx 2.67% of Flippin Bruce Porter Inc’s portfolio.St. Louis Trust Co reduced its stake in PFE by selling 4,724 shares or 25.09% in the most recent quarter. The Hedge Fund company now holds 14,107 shares of PFE which is valued at $499,952. Pfizer makes up approx 0.26% of St. Louis Trust Co’s portfolio.Evergreen Capital Management reduced its stake in PFE by selling 73 shares or 0.2% in the most recent quarter. The Hedge Fund company now holds 36,872 shares of PFE which is valued at $1,358,733. Pfizer makes up approx 0.29% of Evergreen Capital Management’s portfolio.Horan Capital Management reduced its stake in PFE by selling 4,280 shares or 1.49% in the most recent quarter. The Hedge Fund company now holds 283,515 shares of PFE which is valued at $10,416,341. Pfizer makes up approx 2.77% of Horan Capital Management’s portfolio.Private Vista boosted its stake in PFE in the latest quarter, The investment management firm added 13 additional shares and now holds a total of 6,148 shares of Pfizer which is valued at $225,509. Pfizer makes up approx 0.07% of Private Vista’s portfolio.
Pfizer opened for trading at $35.05 and hit $35.17 on the upside on Monday, eventually ending the session at $35.11, with a gain of 0.37% or 0.13 points. The heightened volatility saw the trading volume jump to 1,23,54,034 shares. Company has a market cap of $212,965 M.
On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.
Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.